September 07, 2026 08:09 pm (IST)

Make this your homepage

All Finance

‘No one can dictate what Bengalis eat’: BJP’s blunt message amid Bageshwar Baba’s Durga Puja food row | Delhi hostel collapse: Owner detained after seven die in Satya Niketan tragedy | No Muslims, Aadhaar card and tilak mandatory: VHP lays down rules for Garba, Dandiya in Maharashtra | 'No non-veg near Durga Puja pandals': Bageshwar Baba's big Bengal appeal sparks controversy | 'Law will take its action': Vijay's zero tolerance on insulting women weeks after Udhayanidhi's arrest | Delhi Metro's big warning to content creators: Don't try this viral stunt or face action | Hindutva influencer Swatantra Bhardwaj detained after viral assault clip; Chirag Paswan’s party files complaint for ‘falsely’ naming him | Bengaluru horror: Woman stripped, assaulted and filmed over unpaid loan interest; 4 arrested | West Bengal CM's big warning: Teacher suspended over tilak row, govt employee punished for PM Modi post | Tragedy on Kerala Highway: 8 Tamil Nadu students killed after car crashes into parked lorry

Dr Reddy's acquires rights to an investigational anti-cancer agent

India blooms News Service | | Mar 31, 2016, at 07:47 pm

Hyderabad, Mar 31 (IBNS) Dr Reddy's Laboratories, an integrated pharmaceutical company, announced on Thursday that it has entered into a licensing agreement with Eisai Company Limited of Japan, by which Dr Reddy's will be granted exclusive worldwide development and commercialization rights (excluding Japan and Asia) for Eisai's investigational anticancer agent E7777.

Eisai will develop and market E7777 in Japan and Asia; Dr Reddy's holds the option for rights to develop and market the agent in India, the company said.

In exchange of these rights, Eisai will receive milestone payments in line with obtaining marketing approval and the achievement of agreed upon sales targets.

Raghav Chari, Executive Vice President, Proprietary Products Group, Dr Reddy's Laboratories, said, "E7777 has significant potential as an important component of systemic therapy for cutaneous T-cell lymphoma (CTCL). This therapy represents an extension of our current efforts in the dermatology space to an important segment of skin-related cancers."

#Raghav Chari # Executive Vice President # Proprietary Products Group # Dr Reddy

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.

India
International

Related Images

In Images: Amit Shah performs 'Bhoomi Pujan' of Amul's curd manufacturing plant in Kolkata Jul 19, 2026, at 10:57 pm

Nirmala Sitharaman presents Budget 2025 Feb 01, 2025, at 03:41 pm

Veedol signs former Indian skipper Sourav Ganguly as brand ambassador Jun 29, 2024, at 06:38 am